Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevail Therapeutics

- PMLiVE

CHMP recommends Merck & Co’s Lantus biosimilar

Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo

Deal Watch October 2016

Allergan, Astellas, AstraZeneca, Boehringer Ingelheim and Eli Lilly feature in this month's pharma deals round-up

Eli Lilly HQ

Lilly promises solanezumab news in Alzheimer’s ‘before year-end’

If anti-amyloid drug proves effective, sales could reach $7.5bn according to analysts

- PMLiVE

Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

Eli Lilly HQ

Lilly snags first approval for sarcoma drug Lartruvo

Granted accelerated approval by the FDA becoming first front-line STS therapy for 40 years

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

At current progress, 2025 Alzheimer’s target ‘unlikely to be reached’

Drug development and diagnosis process requires shake-up to create effective therapies

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links